Medicines & supplements – Current GIS Alerts 2026
Found 734 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Paracetamol Aflofarm
Problem achieving a homogeneous suspension and residual sediment at the bottom of the bottle despite shaking; product information lacked a specified minimum shaking time. Potential effects: uneven dosing and reduced efficacy, risk of incorrect dosing.
Enema
Turbidity of the solution observed in selected batches; cause unknown, possible contamination or reduced product quality. Potential effects: poisoning, lack of efficacy, adverse reactions.
Pulmopect
Non-uniform syrup consistency and presence of a gel-like floating substance not dissolving on shaking; out-of-specification result for microbiological purity. Potential effects: infections, risk of infection.
Pulmopect
non-homogeneous syrup consistency and presence of gel-like floating substance not dissolving upon shaking; OOS result for microbiological purity. Potential effects: infection, poisoning, risk of complications.
Enema
Sediment in bottles in the form of solid white particles and turbidity of the solution not meeting product specification. Potential effects: reduced efficacy, irritation, impaired product quality.
Enema
Detected sediment as solid white flakes and turbidity of the solution, inconsistent with specification (product should be clear and free of mechanical impurities). Potential effects: irritation, infection risk, reduced efficacy.
Adrimax
Localized turbidity of the Adrimax syrup solution detected in archived packages, indicating non-conforming appearance and potential loss of quality. Potential effects: poisoning, lack of efficacy, adverse reactions.
Pulmopect
Altered appearance: visible turbidity and jelly-like particles floating in the syrup, not dissolving after shaking; traces of leakage from the packaging. Potential effects: poisoning, lack of efficacy of treatment, adverse reactions.
Hydroxyzinum Hasco
An increase of an unknown contaminant was detected in the 'other single' impurity parameter (hydroxyzine hydrochloride impurity) in batches 010624 and 020624. Potential effects: poisoning, reduced efficacy, adverse reactions.
Hydroxyzinum Hasco
An increase of an unknown impurity was detected in the 'other single' parameter for hydroxyzine hydrochloride after a production pH-meter failure, resulting in non-compliance with quality specifications. Potential effects: unknown toxic effects, adverse reactions, reduced medicine quality.
BIOFLEKS % 0.9 Izotonik Sodyum Klorür çözeltisi Steril
Observed presence of liquid between the primary container and outer film of unknown origin, indicating possible leakage of a parenteral container. Potential effects: infection, loss of sterility, unpredictable consequences upon administration.
Sugammadex Reig Jofre
The presence of visible silicone particles in the product solution was found; the safety report indicates that potential risk to patients from injection of these particles cannot be excluded. Potential effects: vascular complications, inflammatory reactions, emboli, other injection-related complications.
Sugammadex Reig Jofre
The submitted safety assessment report indicates that potential risk to patients from injection of visible silicone particles cannot be excluded. Potential effects: complications after injection, local or systemic reactions, health risk.
Euvax B
Due to the occurrence of a threat to public health and a reported adverse post‑vaccination reaction potentially related to administration of this vaccine, the authority identified a real risk to patients’ health and life. Potential effects: serious adverse reactions, post‑vaccination complications, life‑threatening conditions.
Strepsils z miodem i cytryną
Contamination of the medicinal product with a substance of unknown origin and nature creates a real risk of unforeseeable medical consequences. Potential effects: poisoning, adverse reactions, lack of treatment efficacy.
Atofab
Out-of-specification results for atomoxetine content and capsule mass uniformity (OOS) detected in reference tests. Potential effects: reduced efficacy of the medicine.
Atofab
Out-of-specification results for atomoxetine content and non-uniform capsule mass, which may reduce product efficacy. Potential effects: reduced or absent therapeutic effect.
Atofab
Results out of specification (OOS) for atomoxetine content and non-uniformity of capsule mass in identified batches. Potential effects: reduced therapeutic efficacy.
Atofab
Out-of-specification results for atomoxetine content and non-uniform capsule mass caused by manufacturing defects and changed API particle properties. Potential effects: reduced efficacy of the medicine.
Corhydron 25
A quality defect was identified consisting of an out-of-specification result for free hydrocortisone content, with this exceedance expected to increase until the end of the shelf-life of batch 110021. Potential effects: reduced efficacy or unpredictable action of this life-saving emergency medicine.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.